Reply letter to 'Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial'

Autor:	Sanjay Hadigal, Laura Colombo, Scott Haughie
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	number needed to vaccinate standard-dose quadrivalent vaccine high-dose quadrivalent vaccine vaccine shortage at-risk group prioritization vaccine coverage influenza vaccine flu Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950
Zdroj:	Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Druh dokumentu:	article
ISSN:	2164-5515 2164-554X 21645515
DOI:	10.1080/21645515.2022.2085470
Popis:	A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/7fb7947901144b1284662f2cbd7108d2 Zobrazit plný text záznamu View record in DOAJ